Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Wyeth Research Division of Wyeth Pharmaceuticals Inc
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
To evaluate the safety and to determine the maximum tolerated dose (MTD), if reached, of TRU 015 in subjects with relapsed or refractory B cell NHL.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
The study objective is to compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
Estudio de Fase I/II de HKI-272 en combinación con trastuzumab (Herceptin) en sujetos con cáncer de mama avanzado A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Primary objectives: Part 1: To assess the safety and tolerability, and to define the MTD of orally administered HKI-272 in combination with trastuzumab in subjects with advanced breast cancer. Part ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom
- To demonstrate that the immune response induced by NeisVac-C or Pediacel given with 13vPnC is noninferior to the immune response induced by NeisVac-C or Pediacel given with 7vPnC when measured 1 mon...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 2, Multicenter, Randomized, Active-Controlled, Parallel-Group, Dose-Finding and Safety Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) in Subjects With Decreased Bone Mineral Density
The primary objective of this study is to show increased BMD of the proximal femur (total hip BMD) after injection of rhBMP-2/CPM (either 1.0 mg/mL or 2.0 mg/mL) as an adjunct to systemic osteoporosis...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 4 ans
A 10-MONTH OPEN-LABEL EVALUATION OF THE LONG-TERM SAFETY OF DVS-233 SR IN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
The primary study objective is to evaluate the long-term safety of DVS-233 SR during open-label treatment of outpatients with Major Depressive Disorder (MDD).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain
The primary objectives are: 1) To establish the dose-response relationship of MOA-728 by observing spontaneous bowel movements, and to establish appropriate doses to take into confirmatory phase 3 stu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company
MAJ Il y a 4 ans
An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation
To evaluate efficacy and safety of inotuzumab ozogamicin in combination with rituximab when used as induction therapy prior to consolidation with HD chemo and aSCT in subjects with relapsed/refractory...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMENT AND POST TREATMENT IN REPRODUCTIVE-AGED WOMEN
-To evaluate the superiority of ERB-041 relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive-aged women using the Biber...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECTS WITH TYPE II DIABETES MELLITUS
To determine the glucose lowering effects of PPM-204 in subjects with type 2 diabetes mellitus.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
Suivant